Mast Cells Enhance Myeloma Engraftment and Promote Bone Destruction in the NSG-hIL6 Patient Derived Xenograft Model
Hasanali, Z.; Garfall, A.; Vogl, D.; Cohen, A.; Waxman, A.; Susanibar-Adaniya, S.; Kapur, S.; Stadtmauer, E.; Cipriano, C.; Weber, K.; Allman, D.
Show abstract
Multiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to show mast cells decrease time to engraftment, promote increased myeloma engraftment and cause myeloma bone disease. We identify 10 mast cell secreted factors that together improve the survival of patient myeloma cells in vitro. Our results highlight the versatility of the NSG-hIL6 model to study microenvironmental interactions between human bone marrow cells and myeloma and confirm prior suggestions that clinical signs of disease, such as osteolytic lesions, may at least partially be related to non-malignant bone marrow microenvironmental cells, such as mast cells.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.